<DOC>
	<DOCNO>NCT00586443</DOCNO>
	<brief_summary>Targeting molecular pathway tumor growth become major focus anti-cancer treatment . This study aim investigate toxicity , pharmacokinetics , preliminary efficacy triplet combination bevacizumab , RAD001 , panitumumab patient refractory solid tumor . This open-labeled , non-randomized phase I trial bevacizumab , everolimus panitumumab design assess safety , tolerability efficacy combination adult patient advance solid tumor .</brief_summary>
	<brief_title>BEP Study Phase I ( Bevacizumab , Everolimus , Panitumumab )</brief_title>
	<detailed_description>EGFr inhibition show down-regulatory effect VEGF expression angiogenesis . The combination anti-VEGF anti-EGFr target clinically rational , preliminarily show least additive , synergistic effect [ 12 , 13 ] . Further , preclinical data show constitutive activation AKT pathway mechanism resistance EGFr inhibitor [ 14 ] . Therefore , inhibition EGFr AKT pathways panitumumab RAD001 may create synergistic antitumor effect . There also rationale RAD001 anti-VEGF therapy may synergistic . Preliminary result Phase I dose escalation study bevacizumab combination RAD001 report recommended Phase II dose combination , describe minor response colorectal cancer patient previously refractory bevacizumab-based therapy , 10 month stable disease another colorectal cancer patient previous refractory bevacizumab-based therapy [ 15 ] . Bevicizumab ( Avatstin ) humanize monoclonal antibody VEGF . VEGF know play pivotal role tumor angiogenesis significant mitogenic stimulus arterial , venous lymphatic endothelial cell . The addition bevacizumab chemotherapy show increase overall response rate , duration response survival patient metastatic colon cancer ( 4 ) beneficial first line non-small cell lung cancer metastatic breast cancer [ 1 , 2 ] , second line metastatic colorectal cancer ( 7 ) . VEGF signal phosphoatidylinositol 3-kinase ( PI3K ) Akt well extracellular regulate kinase ( ERK 1/2 ) , mitogen activate protein kinase ( MAPK ) . VEGF 's multiple biologic action may mediate different pathway . Erikkson demonstrate VEGF induce hyperpermeability highly dependent activation AKT pathway , angiogenic effect largely unaffected block pathway likely depend ERK activation [ 3 ] . RAD001 ( Everolimus ) , oral derivative rapamycin , selectively inhibits mTOR ( mammalian target rapamycin ) , intracellular protein kinase implicate control cellular proliferation activate T-lymphocytes neoplastic cell . mTOR consider downstream component PI3K/AKT/TSC pathway , signal module know heavily deregulate many human cancer [ 4 , 5 ] . In context , increase body evidence suggest AKT regulate mTOR activity [ 5-7 ] , activation status PI3K/AKT pathway may indicative responsiveness rapamycins RAD001 . Specifically , loss PTEN constitutive/hyper-activation AKT suggest sensitize tumor effect inhibition mTOR [ 6-8 ] . Indeed , RAD001 preferentially inhibit proliferation tumor cell display high AKT activity totally reverse AKT-driven prostate intraepithelial neoplasia mouse transgenic model [ 7 ] . Rapamycins also inhibit downstream signaling pathway VEGF . The rapamycin-regulated PI3K p70s6 pathway know involved mediate VEGF 's effect endothelial cell [ 9 ] . In animal model , rapamycins modestly decrease tumor VEGF expression , significantly blunt typical angiogenic response VEGF . Everolimus show inhibit tumor growth reduce number blood vessel murine melanoma model , indicate RAD001 direct antiangiogenic effect [ 10 ] . Panitumumab ( Vectibix ) fully humanize monoclonal antibody direct epidermal growth factor receptor ( EGFr ) , 170-kD transmembrane glycoprotein cytoplasmic protein kinase domain essential tumor growth division . The receptor bind multiple ligand include epidermal growth factor transform growth factor-alpha ( TGF-alpha ) . The tyrosine kinase intracellular domain receptor activate via bind ligand EGFr , turn initiate cascade intracellular signal . These downstream signal pathway include phosphorylation mitogen-activated protein kinase ( MAPK ) ras/raf pathway . Inhibition signal pathway result cell growth arrest apoptosis , respectively [ 11 ] . 1 . Sandler , A.B. , et al . Randomized phase II/III trial paclitaxel ( P ) plus carboplatin ( C ) without bevacizumab ( NSC # 704865 ) patient advance non-squamous non-small cell lung cancer ( NSCLC ) : An Eastern Cooperative Oncology Group ( ECOG ) Trial- E4599 . Proc Am Soc Clin Oncol . 2005 . 2 . Miller , K.D. , et al . E2100 : A randomized phase III trial paclitaxel versus paclitaxel plus bevacizumab first line threapy locally recurrent metastatic breast cancer . American Society Clinical Oncology . 2005 . Orlando , FL . 3 . Eriksson , A. , et al. , Small GTP-binding protein Rac essential mediator vascular endothelial growth factor-induced endothelial fenestration vascular permeability . Circulation , 2003 . 107 ( 11 ) : p. 1532-8 . 4 . Vivanco , I. C.L . Sawyers , The phosphatidylinositol 3-kinase-akt pathway human cancer . Nature Cancer , 2002 . 2 : p. 489-501 . 5 . Krymskaya , V.P. , Tumor suppressor hamartin tuberin : intracellular signaling . Cell Signal , 2003 . 15 : p. 729-739 . 6 . Bjornsti , M.-A . P.J . Houghton , The TOR pathway : A target cancer chemotherapy . Nat Rev Cancer , 2004 . 4 : p. 335-348 . 7 . Majumder , P.K. , et al. , mTOR inhibition reverse Akt-dependent prostate intraepithelial neoplasia regulation apoptotic HIF-1-dependent pathway . Nat Med , 2004 . 10 : p. 594-601 . 8 . Noh , W.C. , et al. , Determinants rapamycin breast cancer cell . Clin Cancer Res , 2004 . 10 : p. 1013-1023 . 9 . Yu , Y. J.D . Sato , MAP kinases , phosphatidylinositol 3-kinase , p70 S6 kinase mediate mitogenic response human endothelial cell vascular endothelial growth factor . J Cell Physiol , 1999 . 178 ( 2 ) : p. 235-46 . 10 . Lane , H. , et al . Antiangiogenic activity RAD001 , orally active anticancer agent . Proc AACR . 2002 . 11 . Ciardiello , F. G. Tortora , A novel approach treatment cancer : Targeting epidermal growth factor receptor . Clin Cancer Res , 2001 . 7 : p. 2958-2970 . 12 . Spigel , D.R. , et al . Bevacizumab erlotinib treatment patient metastatic renal cell cancer ( RCC ) : Update phase II multicenter trial . Proc Am Soc Clin Oncol . 2005 . 13 . Saltz , L.B. , et al . Randomized phase II trial cetuximab/bevacizumab/irinotecan ( CBI ) versus cetuximab/bevacizumab ( CB ) irinotecan-refractory colorectal cancer . Proc Am Soc Clin Oncol . 2005 . 14 . She , Q.B. , et al. , Resistance gefitinib PTEN-null HER-overexpressing tumor cell overcome restoration PTEN function pharmacologic modulation constitutive phosphatidylinositol 3'-kinase/Akt pathway signal . Clin Cancer Res , 2003 . 9 ( 12 ) : p. 4340-6 . 15 . Zafar , Y. , et al . Preliminary result phase I study bevacizumab ( BV ) combination everolimus ( E ) patient advance solid tumor . Proc Am Soc Clin Oncol . 2006 .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . Disease must measurable evaluable RECIST criterion . Patients must radiation therapy , hormonal therapy , biologic therapy chemotherapy cancer within 28 day prior study day 1 . Patients must major surgery within 28 day prior study day 1 minor surgical procedure within 7 day prior study day 1 . Age &gt; 18 year . Karnofsky performance status &gt; 70 % . Life expectancy least 3 month . Patients must normal organ marrow function define : **Absolute neutrophil count great equal 1,500/μl ; Platelets great equal 100,000/μl ; Total bilirubin , less equal 1.5 X upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) less equal 2.5 X ULN less equal 5 X ULN know hepatic metastasis ; Creatinine clearance great equal 50 mL/min/m2 patient creatinine level ( CockroftGault equation 24 hour urine ; Hemoglobin &gt; 9 g/dL ; Magnesium &gt; 1.2 mg/dL ; Calcium ( correct albumin ) &gt; 8.7 mg/dL The effect investigational drug develop human fetus know , drug likely embryo feto toxic . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant partner participate study , inform treat physician study PI immediately . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . Ability understand willingness sign write informed consent document . Patients radiation therapy , hormonal therapy , biologic therapy , chemotherapy cancer within 28 day prior day 1 study . Patients receive investigational agent within 28 day prior day 1 study . Patients know CNS metastasis centrallylocated nonsmall cell lung cancer . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg ) Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy . Patients full dose anticoagulation exclude trial . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment ( 56 day hepatectomy , thoracotomy , neurosurgery ) anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer , bone fracture Proteinuria screening demonstrate Urine protein : creatinine ( UPC ) ratio great 1.0 Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment History intolerance hypersensitivity prior treatment bevacizumab , RAD001 , panitumumab . Prior treatment agent otherwise permit . Chronic treatment systemic steroid another immunosuppressive agent , though steroid may use asneeded basis ie treatment nausea . Treatment megace permit treatment anorexia . Other concurrent severe and/or uncontrolled medical disease could compromise safety treatment ( i.e. , severely impaired lung function , uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , ventricular arrhythmia , active ischemic heart disease , chronic liver renal disease , active upper GI tract ulceration ) A known history HIV seropositivity , hepatitis C virus , acute chronic active hepatitis B infection . Impairment gastrointestinal function gastrointestinal disease may significantly alter drug absorption ( e.g. , inflammatory bowel disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome significant small bowel resection ) Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumarin ) Patients unwilling unable comply protocol Medical need continue administration follow drug affect CYP3A . ( see Appendix A ifor list common medication ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit safety compliance study requirement may interfere interpretation result . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>avastin</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase 1</keyword>
	<keyword>combination therapy</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>RAD001</keyword>
	<keyword>everolimus</keyword>
	<keyword>pantitumumab</keyword>
</DOC>